Analysts Set Regulus Therapeutics Inc. (RGLS) PT at $3.00
Regulus Therapeutics Inc. (NASDAQ:RGLS) has received a consensus rating of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $3.00.
Several research firms have recently issued reports on RGLS. Chardan Capital reduced their target price on Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating for the company in a report on Tuesday, June 13th. Wedbush reaffirmed an “ourperform” rating and set a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, August 7th. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 19th. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research report on Wednesday, August 2nd. Finally, BMO Capital Markets set a $1.00 price target on shares of Regulus Therapeutics and gave the company a “hold” rating in a research report on Monday, June 12th.
In related news, CFO Daniel R. Chevallard acquired 54,945 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were acquired at an average price of $0.91 per share, with a total value of $49,999.95. Following the acquisition, the chief financial officer now owns 59,415 shares of the company’s stock, valued at approximately $54,067.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William H. Rastetter acquired 274,725 shares of the company’s stock in a transaction that occurred on Tuesday, July 25th. The shares were bought at an average cost of $0.91 per share, for a total transaction of $249,999.75. The disclosure for this purchase can be found here. Insiders have purchased a total of 549,450 shares of company stock worth $500,000 over the last 90 days. 4.80% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of RGLS. EcoR1 Capital LLC increased its position in shares of Regulus Therapeutics by 145.6% during the second quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock valued at $3,656,000 after buying an additional 2,199,144 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Regulus Therapeutics by 189.1% in the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after acquiring an additional 240,890 shares during the period. South Dakota Investment Council boosted its position in shares of Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock valued at $2,190,000 after acquiring an additional 186,130 shares during the period. LMR Partners LLP bought a new position in shares of Regulus Therapeutics in the second quarter valued at approximately $164,000. Finally, GSA Capital Partners LLP bought a new position in shares of Regulus Therapeutics in the second quarter valued at approximately $139,000. 21.92% of the stock is owned by institutional investors and hedge funds.
Regulus Therapeutics (RGLS) traded up 5.60% during mid-day trading on Wednesday, hitting $1.32. The stock had a trading volume of 2,880,636 shares. Regulus Therapeutics has a 1-year low of $0.79 and a 1-year high of $3.65. The stock’s market cap is $137.00 million. The firm’s 50-day moving average price is $1.10 and its 200-day moving average price is $1.24.
Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. On average, equities analysts expect that Regulus Therapeutics will post ($1.02) earnings per share for the current year.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.